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HPMC capsuleAbstract In this present research work, the aim was to develop ileo-colonic targeted matrix-mini-
tablets-ﬁlled capsule system of Naproxen for chronotherapeutic treatment of Rheumatoid Arthritis.
So Matrix-mini-tablets of Naproxen were prepared using microsomal enzyme dependent and pH-
sensitive polymers by direct compression method which were further ﬁlled into an empty HPMC
capsule. The compatibility was assessed using FT-IR and DSC studies for pure drug, polymers
and their physical mixtures. The prepared batches were subjected to physicochemical studies, drug
content estimation, in-vitro drug release and stability studies. When FTIR and DSC studies were
performed, it was found that there was no interaction between Naproxen and polymers used.
The physicochemical properties of all the prepared matrix-mini-tablets batches were found to be
in limits. The drug content percentage in the optimized formulation F18 was found to be
99.24 ± 0.10%. Our optimized matrix-mini-tablets-ﬁlled-capsule formulation F18 releases
Naproxen after a lag time of 2.45 ± 0.97 h and 27.30 ± 0.86%, 92.59 ± 0.47%, 99.38 ± 0.69%
at the end of 5, 8, 12 h respectively. This formulation was also found to be stable as per the guide-
lines of International Conference on Harmonisation of Technical Requirements of Pharmaceuticals
for Human Use. Thus, a novel ileo-colonic targeted delivery system of Naproxen was successfully
developed by ﬁlling matrix-mini-tablets into an empty HPMC capsule shell for targeting early
morning peak symptoms of rheumatoid arthritis.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Rheumatoid arthritis is a chronic inﬂammatory syndrome
which causes the destruction of joints integrity. The patients
with this disease have joint pain and functional disability
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(Cutolo, 2012). These symptoms occur due to diurnal varia-
tions in the levels of circulating proinﬂammatory cytokines,
interleukin-6 and/or tumor necrosis factor-a (Arvidson et al.,
1994). The concept of chronotherapy can be used for the better
treatment of Rheumatoid arthritis so that the highest amount
of drug can be maintained in the bloodstream during the early
morning time (Buttgereit et al., 2011; Najmuddin et al., 2010).
In this case, colon targeting of drug or intentionally delayed
absorption can be preferable in order to have a uniform thera-
peutic effect. Because the drug can be delivered in more
amount during its greatest need as the release of drug occurs
after a lag time. Thus, the peak pain and stiffness symptoms
of the disease can be overcome and good patient compliance
can be achieved (Gothaskar et al., 2004; Krishainah and
Satyanarayan, 2001). Dew et al., developed the ﬁrst colonic
targeted pH responsive drug delivery system and it is most
speciﬁcally referred to as ‘ileo-colonic targeted drug delivery’
rather than colonic targeted drug delivery system (Dew
et al., 1982; Evans et al., 1988; Ibekwe et al., 2008, 2006).
A number of approaches can be used for targeting the
drugs at the colonic junction. Some of them are by using
enzyme and pH dependent approaches (Chickpetty et al.,
2010). In the enzyme dependent approach, it makes use of such
carriers or polymers which are degraded by enzymes produced
by the colonic bacteria. Because the microﬂora is rich in colo-
nic region and their energy needs are fulﬁlled by fermenting
various substrates types that have been left undigested in the
small intestine such as disaccharides, trisaccharides and
polysaccharides. For their fermentation to take place, the
microﬂora produces a vast number of enzymes such as
azoreductase, arabinosidase, glucuronidase, galactomannase,
galactosidase, nitroreductase, xylosidase, deaminase and
ureadehydroxylase. As these enzymes are mainly present only
in the colon, the use of enzyme degradable polymers such as
natural polysaccharides from plant origin (for e.g. Guar
gum) and algal origin (for e.g. Alginates) seems to be the most
interested for colonic targeted drug delivery (Mohapatra et al.,
2011). Whereas in the pH dependent approach, it depends on
the increased pH of the gastrointestinal tract i.e. from stomach
(pH 1.5–3) to terminal ileum (pH 7–8) Akhgari et al., 2005.
Mini-tablets are very small tablets whose diameter is equal
to or smaller than 3 mm that can be either placed in sachets or
ﬁlled into a capsule shell for easy administration (Lopes et al.,
2006; Hadi et al., 2012; Siaboomi, 2009; Mirela et al., 2010).
They are having several beneﬁts over single unit larger tablets
such as consistent drug release, uniform clinical performance,
more ﬂexibility during the formulation development and
maximum stability on storage (Siaboomi, 2009; Mirela et al.,
2010). Also mini-tablets are easier to prepare using direct
compression method, which involves very less number of
steps using simple equipments for their manufacture. Thus,
the time and costs can be saved. Other beneﬁts include regular
shapes and excellent size uniformity (Lopes et al., 2006; Hadi
et al., 2012; Siaboomi, 2009; Mirela et al., 2010; Fegely,
2009; Maghsoodi and Kiafar, 2013). In the present work, the
reason for designing matrix-mini-tablets-ﬁlled capsule
formulation is to develop a more reliable dosage form which
possess all the advantages of a single unit bigger tablet and
yet the problems such as danger of dose dumping and alter-
ation in release proﬁle of drug due to unit to unit variation
can be avoided.Naproxen is a derivative of naphthylpropionic acid which
belongs to the class of NSAID’s and it has been found to be
effective in both experimental and clinical pain of rheumatoid
arthritis (Uziel et al., 2000). So, an attempt was made to
develop matrix-mini-tablets of Naproxen ﬁlled in a capsule
for treating the early morning peak symptoms of rheumatoid
arthritis.2. Materials and methods
2.1. Materials
Naproxen was obtained as a gift sample from IPS Pharma
Training Institute, Hyderabad, India. pH sensitive polymers
(Eudragit L-100 and Eudragit S-100) were obtained as gift
samples by Degussa India Pvt. Ltd., Mumbai, India. Sodium
alginate, Guar gum, Microcrystalline cellulose Avicel PH102
and Aerosil were purchased from SD Fine Chemicals,
Mumbai, India. Magnesium stearate was purchased from
Himedia Chem Lab, Mumbai, India. Empty HPMC capsules
of almost all sizes were obtained as gift samples from ACG
Associated capsules Pvt. Ltd. Mumbai, India. All other
remaining materials used were of analytical grade.
2.2. Preformulation studies
2.2.1. Procedure for Fourier Transform Infrared (FTIR)
spectral analysis
The compatibility for pure drug Naproxen, polymers and their
physical mixtures used in this experimental procedure was
evaluated by recording of spectra using FT-IR
Spectrophotometer (Perkin Elmer, spectrum-100, Japan).
The spectra were recorded by taking 5% of sample in potas-
sium bromide (KBr) and after this mixture was grounded into
a ﬁne powder it was compressed into KBr pellets at 4000 Psi
compaction pressure for a period of 2 min. The resolution
was 1 cm1 and the range of scanning was 400–4000 cm1
(Hadi et al., 2014a,b).
2.2.2. Procedure for diffraction scanning calorimetric (DSC)
studies
The DSC thermograms of pure drug Naproxen and their
physical mixtures were recorded using Diffraction scanning
calorimeter (DSC 60, Shimadzu, Japan). Their measurement
was taken between 30 and 350 C at a heating rate of
10 C/min (Hadi et al., 2014a,b).
2.3. Formulation methods
2.3.1. Procedure for the preparation of matrix-mini-tablets of
Naproxen
Matrix-mini-tablets of Naproxen were prepared using direct
compression method as shown in Table 1. In the ﬁrst step
Naproxen, polymer or polymers and Microcrystalline cellulose
were passed through the 60 mesh sieve and after weighing as per
the formulation table they were mixed. Then in the second
step, magnesium stearate and aerosil were passed separately
through the same sieve and after weighing as per the
formulation table they were added to the above mixture and
blended thoroughly. This prepared blend was then compressed
Table 1 Composition of matrix-mini-tablets of Naproxen.
F.C Naproxen Guar
gum
Sodium
alginate
Eudragit L-
100
Eudragit S-
100
Microcrystalline cellulose (Avicel
PH102)
Magnesium
stearate
Aerosil
F1 16.666 2 – – – 6.084 0.125 0.125
F2 16.666 4 – – – 4.084 0.125 0.125
F3 16.666 6 – – – 2.084 0.125 0.125
F4 16.666 8 – – – 0.084 0.125 0.125
F5 16.666 2 2 – – 4.084 0.125 0.125
F6 16.666 2 4 – – 2.084 0.125 0.125
F7 16.666 2 6 – – 0.084 0.125 0.125
F8 16.666 4 2 – – 2.084 0.125 0.125
F9 16.666 4 4 – – 0.084 0.125 0.125
F10 16.666 6 2 – – 0.084 0.125 0.125
F11 16.666 – – 2 – 6.084 0.125 0.125
F12 16.666 – – 4 – 4.084 0.125 0.125
F13 16.666 – – 6 – 2.084 0.125 0.125
F14 16.666 – – 8 – 0.084 0.125 0.125
F15 16.666 – – – 2 6.084 0.125 0.125
F16 16.666 – – – 4 4.084 0.125 0.125
F17 16.666 – – – 6 2.084 0.125 0.125
F18 16.666 – – – 8 0.084 0.125 0.125
F19 16.666 – – 2 2 4.084 0.125 0.125
F20 16.666 – – 2 4 2.084 0.125 0.125
F21 16.666 – – 2 6 0.084 0.125 0.125
F22 16.666 – – 4 2 2.084 0.125 0.125
F23 16.666 – – 4 4 0.084 0.125 0.125
F24 16.666 – – 6 2 0.084 0.125 0.125
Note: 2 = 8%; 4 = 16%; 6 = 24%; 8 = 32% as total weight of each matrix-mini-tablet was 25 mg.
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in a rotary tablet press (Model RSB-4, Rimek mini-press,
Karnavati Engineering, Ahmedabad) (Hadi et al., 2014a).
2.3.2. Procedure for the preparation of matrix-mini-tablets-ﬁlled
capsule formulations
The capsule formulations were prepared by ﬁlling 15 matrix-
mini-tablets equivalent to 250 mg of Naproxen into size ‘0’
HPMC capsule (as shown in Fig. 1) (Hadi et al., 2014a,b).
2.4. Evaluation methods
2.4.1. Procedure for pre-compression parameters
The prepared powder blends of formulation batches were
evaluated for pre-compression parameters in order to study
their ﬂow properties and to maintain matrix-mini-tablets
weight uniformity.
2.4.1.1. Angle of repose (h). The angle of repose was deter-
mined by taking accurately weighed quantity of powder blend
into the funnel. The funnel height was adjusted such that theFigure 1 (a) Matrix-mini-tablets and (b) matfunnel tip should touch the apex of blend. This blend was then
allowed to freely ﬂow through the funnel onto the surface.
From the formed powder cone, radius and height were
measured and their angle of repose was calculated using the
following equation (Hadi et al., 2014a,b).
tan h ¼ h=r
where h and r are the height and radius of the formed
powder cone respectively.
2.4.1.2. Loose Bulk density (LBD) and Tapped Bulk density
(TBD). Both the LBD and TBD were determined by accu-
rately weighing 2gm of powder blend from each formulation
batch which was previously shaken to break any agglomerates
formation, and were introduced into 10 ml of measuring cylin-
der. After noting the initial volume, the measuring cylinder
was made to fall under its own weight onto a hard surface
from the height of 2.5 cm at 2 s time intervals. This process
of tapping was continued until a further no change in volume
of powder blend was noted and their LBD and TBD were cal-
culated using the following equations (Hadi et al., 2014a,b).rix-mini-tablets-ﬁlled capsule formulation.
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packing
TBD=Weight of the Granules /Tapped Volume of the
packing
2.4.1.3. Hausner’s ratio. Hausner’s ratio is an indirect index of
ease of powder ﬂow. It was calculated by using the following
equation (Hadi et al., 2014a,b).
Hausner ratio ¼ qt
qd
where, qt is the tapped density and qd is the bulk density.
2.4.1.4. Carr’s compressibility index. Carr’s Index (%) was cal-
culated by using the following equation (Hadi et al., 2014a,b).
Carr’s Indexð%Þ ¼ TBD LBD
TBD
 1002.4.2. Procedure for post-compression parameters
The prepared matrix-mini-tablets of all the formulation
batches were evaluated for post-compression parameters in
order to study their physicochemical properties.
2.4.2.1. Hardness test. The matrix-mini-tablets hardness was
determined using Pﬁzer hardness tester. Three matrix-
mini-tablets were randomly taken from each formulation
batches and their values were calculated (Hadi et al., 2014a,b).
2.4.2.2. Friability test. The Friability test was evaluated by
initially weighing (Winitial) twenty matrix-mini-tablets and
ﬁnally transferring them into a Veego friabilator. TheFigure 2 FTIR spectra of (a) pure drug, Naproxen, (b) Guar gum, (c)
mixture of Naproxen + Guar gum + Sodium alginate and (g) physicfriabilator was operated at 25 rpm and run up to 100
revolutions. Then the matrix-mini-tablets were weighed again
(Wﬁnal) Hadi et al., 2014a,b.The percentage friability was cal-
culated by using the following equation.
%F ¼ Winitial Wfinal
Winitial
 1002.4.2.3. Weight variation test. The Weight variation test was
evaluated by randomly taking twenty matrix-mini-tablets from
each formulation batch and weighing them individually to
check their weight variation (Hadi et al., 2014a,b).
2.4.2.4. Uniformity of thickness. The Uniformity of thickness
was evaluated by randomly taking six matrix-mini-tablets
from each formulation batch and measuring them individually
for thickness using screw gauge (Hadi et al., 2014a,b).
2.4.2.5. Drug content uniformity. The drug content uniformity
was estimated by taking ﬁfty matrix-mini-tablets and then
crushing them into ﬁne powder in the mortar. This ﬁne powder
equivalent to 250 mg of Naproxen was extracted into 7.2 pH
phosphate buffer. The buffer solution was then ﬁltered
through a Millipore ﬁlter of 0.45 lm pore size. After suitable
dilutions were done, drug content was determined at a wave-
length of 331 nm using UV-Spectrophotometer (Hadi et al.,
2014a,b).
2.4.3. Procedure for In-vitro dissolution testing of matrix-mini-
tablets-ﬁlled capsule formulations
Dissolution testing evaluation was performed by using USP
XXIII dissolution test apparatus (basket type). OneSodium alginate, (d) Eudragit L100, (e) Eudragit S100, (f) physical
al mixture of Naproxen + Eudragit L100 + Eudragit S100.
Figure 3 DSC spectra of (a) pure drug Naproxen, (b) physical
mixture of Naproxen + Guar gum + Sodium alginate and (c)
physical mixture of Naproxen + Eudragit L100 + Eudragit S100.
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completely at a time. Three dissolution media with 1.2, 7.4
and 6.8 pH were used sequentially for formulations F1 to
F10 and four dissolution media with 1.2, 6.5, 6.8 and 7.2 pH
were used sequentially for formulations F11 to F24 to main-
tain the conditions of GI tract. These media represent the
stomach (1.2 pH), proximal part of the small intestine (6.5
pH), lower part of the small intestine and colon (6.8 pH), term-
inal ileum (7.2 pH) and whole small intestine (7.4 pH). During
dissolution testing for F1 to F10 formulations, 750 ml of 1.2
pH media was ﬁrst used for two hours, then followed with
900 ml of 7.4 pH phosphate buffer for three hours and was
continued further with 900 ml of 6.8 pH dissolution media
containing 0.05 mg/ml of betagalactomannase enzyme for sub-
sequent hours. Whereas during dissolution testing for F11 to
F24 formulations, 750 ml of 1.2 pH media was ﬁrst used for
two hours, followed by 900 ml of 6.5, 6.8 and 7.2 pH phos-
phate buffers for one, two and subsequent hours respectively.
Rotation speed and temperature were maintained at 100 rpm
and 37 ± 0.5 C respectively. At ﬁxed time intervals (0, 1, 2,
3, 4, 5, 6, 7, 8, 10 and 12 h), 5 ml of dissolution media was
withdrawn and was then replaced with fresh respective dis-
solution media. The samples withdrawn were analyzed at
230 nm for 1.2 pH media, 329 nm for 6.5 and 6.8 pH media
and 331 nm for 7.2 and 7.4 pH media by UV absorption spec-
troscopy and the drug release percentage was calculated over
the sampling time intervals (Hadi et al., 2014a,b; Kaur et al.,
2010; Wong et al., 1997).
2.4.4. Stability studies
The stability studies for optimized formulation were per-
formed at both room temperature and accelerated stability
conditions. The room temperature storage conditions were
kept at 30 ± 2 C and 65 ± 5% relative humidity (RH) and
for accelerated stability conditions were stored at 40 ± 2 C
and 75 ± 5% RH in a stability chamber. At regular time inter-
vals of three and six months samples were withdrawn from the
stability chamber and were tested for physical parameters such
as Appearance, Weight variation, hardness, thickness,
friability, drug content and In-vitro release proﬁle of matrix-mini-tablets (Hadi et al., 2014a,b; ICH Guidelines, 2003;
Cha et al., 2001).
3. Results and discussion
As the main objective of this research work was to develop a
novel matrix-mini-tablets-ﬁlled capsule formulation which tar-
gets Naproxen at the ileo-colonic junction. So an attempt was
tried by incorporating lowest to highest possible concentra-
tions of individual or combined polymers in the mini-tablets.
As the incorporating capability of size ‘0’ HPMC capsule
(which is the most common largest size easily accepted by
humans) was only 15 mini-tablets and the dose of Naproxen
was also more i.e. 250 mg (so each matrix-mini-tablet weighing
25 mg contains 16.666 mg of Naproxen itself), so it was
possible to use only up to maximum 32% concentration of
polymers in individual matrix-mini-tablets.
The target release proﬁle was based on the assumption that
if the optimized formulation is administered at night 10:00
P.M (before going to bed) then maximum amount of
Naproxen will be available in between 4:00 and 6:00 A.M.
and this is the time when rheumatoid arthritis symptoms will
be at its peak.
3.1. FT-IR studies
In order to evaluate the compatibility, the FT-IR spectra were
recorded in between 400 and 4000 cm1 for pure drug
Naproxen, polymers and their physical mixtures (as shown
in Fig. 2). For the present research Naproxen was used as
the model drug. It has shown AOH, ACH3, ACH3 and
AC‚O stretchings due to the presence of characteristic peaks
at 3166 cm1, 3002 cm1, 2963 cm1 and 1727 cm1 respec-
tively. These are all the characteristic peaks of Naproxen.
The guar gum polymer spectrum has shown AOH, ACH
and ACO stretchings due to the presence of characteristic
peaks at 3382 cm1, 2938 cm1 and 1241 cm1 respectively.
Whereas, the Sodium alginate polymer spectrum has also
shown similar AOH, ACH and ACO stretchings due to the
presence of characteristic peaks at 3567 cm1, 2943 cm1 and
1302 cm1 respectively. The Eudragit L100 polymer spectrum
has shown AOH, AOCH3, ACH3 and AC‚O stretchings due
to the presence of characteristic peaks at 3258 cm1,
2997 cm1, 2952 cm1 and 1731 cm1 respectively. Whereas,
Eudragit S100 polymer spectrum also shows similar –OH,
AOCH3, ACH3 and AC‚O stretchings due to the presence
of characteristic peaks at 3225 cm1, 2998 cm1, 2953 cm1
and 1727 cm1 respectively. When the physical mixture spectra
of Naproxen, guar gum, sodium alginate and Naproxen,
Eudragit L100, Eudragit S100 were recorded, their respective
higher spectrum has shown all the peaks corresponding to
the three constituents. None of the peak was absent, as they
were intact. Thus, it was observed that combination of pure
drug Naproxen and the used polymers can be suitable for
formulating matrix-mini-tablets meant for its desired thera-
peutic purpose (Hadi et al., 2014a,b).
3.2. DSC studies
The above FTIR studies observation was further conﬁrmed by
DSC studies. The DSC thermograms of pure drug Naproxen
Table 2 Physical evaluation results of pre-compression blend.
Formulation
code
Angle of repose ()
±SD, n= 3
Bulk density (gm/cc)
±SD, n= 3
Tapped density (gm/cc)
±SD, n= 3
Carr’s index (%)
±SD, n= 3
Hausner’s ratio
±SD, n= 3
F1 23.670 ± 0.14 0.510 ± 0.01 0.583 ± 0.01 12.56 ± 0.88 1.14 ± 0.01
F2 22.250 ± 0.17 0.513 ± 0.01 0.586 ± 0.01 12.50 ± 1.12 1.14 ± 0.01
F3 24.160 ± 0.20 0.516 ± 0.00 0.593 ± 0.00 12.91 ± 0.92 1.14 ± 0.01
F4 24.320 ± 0.29 0.536 ± 0.01 0.606 ± 0.01 12.25 ± 1.34 1.14 ± 0.01
F5 23.650 ± 0.12 0.523 ± 0.01 0.596 ± 0.01 12.28 ± 0.74 1.14 ± 0.00
F6 22.350 ± 0.22 0.520 ± 0.01 0.586 ± 0.00 11.36 ± 1.04 1.12 ± 0.01
F7 22.570 ± 0.28 0.540 ± 0.01 0.613 ± 0.01 11.94 ± 0.65 1.13 ± 0.00
F8 22.890 ± 0.19 0.546 ± 0.00 0.620 ± 0.01 11.82 ± 0.76 1.13 ± 0.00
F9 24.600 ± 0.22 0.536 ± 0.01 0.610 ± 0.01 12.02 ± 0.96 1.13 ± 0.01
F10 23.610 ± 0.12 0.520 ± 0.01 0.593 ± 0.01 14.04 ± 0.86 1.16 ± 0.01
F11 23.380 ± 0.33 0.546 ± 0.00 0.613 ± 0.00 10.86 ± 0.89 1.12 ± 0.01
F12 22.680 ± 0.24 0.526 ± 0.01 0.600 ± 0.01 12.22 ± 0.97 1.13 ± 0.01
F13 23.990 ± 0.10 0.546 ± 0.01 0.623 ± 0.00 12.29 ± 0.87 1.14 ± 0.01
F14 24.220 ± 0.24 0.520 ± 0.01 0.593 ± 0.00 12.36 ± 1.04 1.14 ± 0.01
F15 24.020 ± 0.18 0.533 ± 0.00 0.620 ± 0.01 10.74 ± 0.79 1.12 ± 0.00
F16 24.750 ± 0.20 0.503 ± 0.00 0.576 ± 0.00 12.71 ± 0.94 1.14 ± 0.01
F17 23.110 ± 0.16 0.540 ± 0.01 0.610 ± 0.01 11.47 ± 0.18 1.12 ± 0.00
F18 23.930 ± 0.22 0.553 ± 0.01 0.620 ± 0.01 10.74 ± 0.64 1.12 ± 0.00
F19 23.840 ± 0.18 0.526 ± 0.01 0.609 ± 0.01 10.23 ± 0.26 1.11 ± 0.00
F20 24.480 ± 0.15 0.550 ± 0.01 0.628 ± 0.01 11.29 ± 0.18 1.12 ± 0.00
F21 24.970 ± 0.11 0.513 ± 0.01 0.576 ± 0.01 10.97 ± 0.79 1.12 ± 0.01
F22 23.070 ± 0.20 0.520 ± 0.01 0.593 ± 0.00 12.36 ± 1.04 1.14 ± 0.01
F23 22.890 ± 0.24 0.510 ± 0.01 0.583 ± 0.01 12.56 ± 0.88 1.14 ± 0.01
F24 22.640 ± 0.17 0.533 ± 0.00 0.606 ± 0.01 12.07 ± 0.71 1.13 ± 0.00
Table 3 Evaluation results of matrix-mini-tablets.
Formulation
code
Weight variation (mg)
(±SD), n= 20
Hardness (kg)
(±SD), n= 6
Thickness (mm)
(±SD), n= 6
Friability (%)
(±SD), n= 20
% Drug content
(±SD), n= 3
F1 25 ± 0.18 2.24 ± 0.08 2.09 ± 0.02 0.57 ± 0.07 99.56 ± 0.12
F2 26 ± 0.06 2.35 ± 0.12 2.05 ± 0.02 0.39 ± 0.05 99.62 ± 0.08
F3 25 ± 0.26 2.28 ± 0.07 2.02 ± 0.01 0.44 ± 0.08 99.11 ± 0.16
F4 24 ± 0.17 2.32 ± 0.15 2.08 ± 0.01 0.33 ± 0.04 99.85 ± 0.10
F5 23 ± 0.25 2.26 ± 0.10 2.06 ± 0.02 0.64 ± 0.09 97.40 ± 0.13
F6 25 ± 0.15 2.25 ± 0.08 2.05 ± 0.01 0.32 ± 0.05 99.31 ± 0.06
F7 26 ± 0.26 2.31 ± 0.10 2.08 ± 0.01 0.47 ± 0.05 98.91 ± 0.10
F8 27 ± 0.20 2.36 ± 0.08 2.05 ± 0.02 0.36 ± 0.08 99.84 ± 0.08
F9 25 ± 0.10 2.38 ± 0.11 2.06 ± 0.02 0.50 ± 0.09 98.96 ± 0.10
F10 27 ± 0.18 2.33 ± 0.16 2.04 ± 0.01 0.43 ± 0.06 99.77 ± 0.06
F11 24 ± 0.16 2.36 ± 0.14 2.09 ± 0.01 0.61 ± 0.08 99.98 ± 0.08
F12 25 ± 0.19 2.29 ± 0.10 2.05 ± 0.01 0.59 ± 0.07 99.06 ± 0.10
F13 24 ± 0.21 2.30 ± 0.13 2.04 ± 0.02 0.57 ± 0.06 99.77 ± 0.12
F14 24 ± 0.10 2.32 ± 0.07 2.10 ± 0.02 0.35 ± 0.05 97.65 ± 0.07
F15 26 ± 0.11 2.36 ± 0.05 2.08 ± 0.02 0.47 ± 0.05 98.93 ± 0.10
F16 26 ± 0.16 2.27 ± 0.14 2.06 ± 0.01 0.26 ± 0.09 99.30 ± 0.08
F17 25 ± 0.29 2.32 ± 0.12 2.08 ± 0.01 0.41 ± 0.07 99.58 ± 0.05
F18 27 ± 0.12 2.20 ± 0.09 2.06 ± 0.02 0.59 ± 0.06 99.24 ± 0.10
F19 25 ± 0.23 2.25 ± 0.06 2.11 ± 0.01 0.29 ± 0.07 98.88 ± 0.06
F20 25 ± 0.15 2.37 ± 0.10 2.03 ± 0.02 0.32 ± 0.05 99.15 ± 0.06
F21 24 ± 0.10 2.39 ± 0.08 2.07 ± 0.01 0.48 ± 0.08 98.02 ± 0.14
F22 26 ± 0.28 2.22 ± 0.12 2.08 ± 0.01 0.31 ± 0.09 99.69 ± 0.10
F23 25 ± 0.20 2.34 ± 0.06 2.09 ± 0.01 0.28 ± 0.10 99.40 ± 0.09
F24 25 ± 0.12 2.28 ± 0.12 2.05 ± 0.01 0.57 ± 0.06 99.32 ± 0.12
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sensitive polymers are shown in Fig. 3. The DSC thermogram
of pure drug Naproxen, corresponding to its melting point
gives a sharp exothermic peak at 160.22 C. However, the
DSC thermograms for physical mixtures of Naproxen, guargum, sodium alginate and Naproxen, Eudragit L100,
Eudragit S100 have not shown any signiﬁcant shift in their
exothermic peaks i.e. their peaks were found at 157.34 C
and 156.76 C, respectively. Thus, the results of DSC thermo-
grams also conﬁrmed that the physical mixtures of drug and
Table 4 Results of in-vitro release studies of Naproxen.
Formulation
code
Lag time in hours
(i.e. time taken
for less than 10%
of Naproxen
release)
Mean %
cumulative
drug release
at the end of
8 h
Mean %
cumulative
drug release at
the end of 12 h
F1 2.01 ± 0.89 99.52 ± 0.82 –
F2 2.12 ± 0.70 99.87 ± 0.90 –
F3 2.36 ± 0.93 98.39 ± 0.44 99.86 ± 0.94+
F4 2.42 ± 0.80 90.16 ± 0.76 99.73 ± 0.52
F5 2.03 ± 0.66 99.95 ± 0.59 –
F6 2.20 ± 1.07 99.80 ± 1.14 –
F7 2.08 ± 0.59 99.74 ± 0.78 –
F8 2.25 ± 1.15 98.60 ± 0.61 99.46 ± 0.70+
F9 2.34 ± 0.61 97.10 ± 0.98 99.85 ± 0.83+
F10 2.40 ± 0.98 91.92 ± 0.39 99.90 ± 0.95+
F11 2.03 ± 0.74 99.97 ± 0.89* –
F12 2.06 ± 0.96 98.61 ± 0.71* –
F13 2.10 ± 0.80 99.57 ± 0.40* –
F14 2.15 ± 0.79 99.86 ± 0.95* –
F15 2.09 ± 0.94 99.10 ± 0.62* –
F16 2.14 ± 0.67 99.47 ± 0.37 –
F17 2.34 ± 1.10 99.69 ± 1.18 –
F18 2.45 ± 0.97 92.59 ± 0.47 99.38 ± 0.69
F19 2.11 ± 0.74 99.94 ± 1.07* –
F20 2.27 ± 0.90 99.47 ± 0.36 –
F21 2.32 ± 0.96 99.20 ± 0.54 –
F22 2.24 ± 0.79 99.74 ± 0.86 –
F23 2.26 ± 0.88 98.26 ± 0.73 99.88 ± 0.92+
F24 2.21 ± 0.94 99.15 ± 0.66 –
Note: *Mark indicates that the Naproxen was released before 8 h.
+Mark indicates that the Naproxen was released before 12 h.
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chemical interaction (Hadi et al., 2014b).
3.3. Evaluation of the powder blend of matrix-mini-tablets
The angle of repose values for the prepared blend of matrix-
mini-tablets were found to range between 22.250 ± 0.17 and
24.970 ± 0.11. The LBD and TBD values were found to range
between 0.503 ± 0.00 and 0.553 ± 0.00 and between
0.576 ± 0.00 and 0.628 ± 0.01 gm/cc respectively. The Carr’s
compressibility index values were found to range between
10.23 ± 0.26 and 14.04 ± 0.86%. The Hausner’s ratio values
were found to range between 1.11 ± 0.00 and 1.16 ± 0.01.
As the values for angle of repose, Carr’s compressibility index
and Hausner’s ratio were found to be less than 30, 15% and
1.25 respectively it indicates good ﬂow properties. Thus, the
prepared powder blend of matrix-mini-tablets was found to
exhibit good ﬂow properties which are evident from the results
shown in Table 2.
3.4. Evaluation of matrix-mini-tablets
The weight variation values of the matrix-mini-tablets were
found to range between 24 ± 0.10 and 27 ± 0.18 mg. The
pharmacopoeial limit for percentage deviation of tablets of
130 mg or less is ± 10% and all the formulation batches were
found to be passed according to the speciﬁcations given in
Indian pharmacopoeia (IP). The values for hardness were
found to be uniform and were found to range between2.20 ± 0.09 and 2.39 ± 0.08 kg. Friability values have also
shown that matrix-mini-tablets have got sufﬁcient strength
and were found to range between 0.26 ± 0.09 and
0.61 ± 0.08%. The values for thickness were found to range
between 2.04 ± 0.01 and 2.11 ± 0.01 mm. Excellent drug
content uniformity was also found in matrix-mini-tablets, as
their values were found to range between 97.40 ± 0.13 and
99.98 ± 0.08% which is more than 95%. Thus, all the post-
compressional parameters of matrix-mini-tablets were found
to be satisfactory as evident from the results shown in Table 3.
3.5. In-vitro dissolution testing of matrix-mini-tablets-ﬁlled
capsule systems
During dissolution testing of formulations, it was found that
the HPMC capsule disintegrated and the matrix-mini-tablets
were released within 9 min in 1.2 pH dissolution media. In
our attempt to target Naproxen at the ileo-colonic junction,
we prepared twenty-four formulations of matrix-mini-tablets
by using Guar gum, Sodium alginate, Eudragit L100 and
Eudragit S100 polymers both in individual and combined
concentrations (i.e. 8%, 16%, 24%, 32%). From the results
of dissolution testing, it was found that all the formulations
except F18 could only prevent the Naproxen release in pH
1.2 buffer but could not prevent the release in. pH 6.5 and
6.8 buffers. However, when compared to all the formulations,
only the release from formulations F18 was found to release
very less amount of naproxen at acidic and intestinal pH and
maximum portion of Naproxen at ileo-colonic pH. Because
it releases Naproxen after a lag time of 2.45 ± 0.97 h and
27.30 ± 0.86%, 92.59 ± 0.47%, 99.38 ± 0.69% at the end
of 5, 8, 12 h respectively. Thus, it was considered to be the best
formulation for matrix-mini-tablets-ﬁlled-capsule formula-
tions of Naproxen. The in-vitro dissolution testing results of
all the matrix-mini-tablets-ﬁlled capsule formulations are
shown in Table 4 and represented in Fig. 4.
3.5.1. Effect of microsomal enzyme dependent polymers (Guar
gum and sodium alginate)
From the in-vitro dissolution proﬁle, it was found that as the
guar gum polymer concentration was increasing the lag time
(i.e. time taken for less than 10% of Naproxen release) was
increased and release rate of Naproxen was decreased. This
is due to the reason that guar gum polymer because of its
microsomal enzyme dependent characteristics has retarded
the release of Naproxen in acidic and intestinal pH buffers
and increased the release in colonic buffer containing
0.05 mg/ml of betagalactomannase enzyme. But when guar
gum and sodium alginate were used as combination polymers,
it was found that the Naproxen release rate was increased
while compared to batches formulated with guar gum alone.
This is due to the reason that sodium alginate has increased
the permeation of Naproxen from guar gum polymer because
of its quickly water absorbing capacity.
3.5.2. Effect of pH dependent polymers (Eudragit L100 and
Eudragit S100)
From the in-vitro dissolution proﬁle, it was found that as the
individual concentrations of both the polymers in matrix-
mini-tablets were increasing the lag time was increased and
release rate of Naproxen was decreased. This is due to the
Figure 4 In-vitro release proﬁle of matrix-mini-tablets-ﬁlled capsule formulations prepared with (a) Guar gum, (b) combination of Guar
gum and Sodium alginate, (c) Eudragit L100, (d) Eudragit S100 and (e) combination of Eudragit L100 and Eudragit S100.
Formulation and evaluation of Naproxen for treatment of rheumatoid arthritis 71reason that Eudragit polymers because of their pH dependent
solubility characteristics have retarded the release of Naproxen
in acidic and intestinal pH buffers and increased the release in
ileo-colonic buffer. But when both the Eudragit L100 and
Eudragit S100 polymers were used in combination, it was
found that the Naproxen release rate was increased from
matrix-mini-tablets while compared to batches formulated
with Eudragit S100 alone. This is due to the reason that the
Eudragit L100 polymer because of its good solubility in 6.5
and 6.8 pH buffers increased the Naproxen permeation from
Eudragit S100 polymer which dissolves at 7.2 pH buffer.3.6. Stability studies
The obtained results of stability studies at both room tempera-
ture and accelerated stability revealed that the optimized
matrix-mini-tablets-ﬁlled capsule formulation did not shown
any signiﬁcant changes in physical stability parameters such
as Appearance, Weight variation, Hardness, Thickness,
Friability, Drug content estimation and In-vitro release proﬁle
of Naproxen during the period of study (as shown in Table 5).
Thus, for the optimized formulation stability was found as per
ICH guidelines.
Table 5 Results of physical stability studies for optimized formulation F18.
Parameters Storage conditions and time (months)
Initial results Room temperature Accelerated stability
30 ± 2 C and 65 ± 5% RH 40 ± 2 C and 75 ± 5% RH
0 3 6 3 6
Appearance White circular
mini-tablets
No change in
appearance
No change in
appearance
No change in
appearance
No change in
appearance
Weight variation (mg) (±SD),
n= 20
27 ± 0.12 27 ± 0.18 26 ± 0.15 26 ± 0.14 25 ± 0.10
Hardness (kg) (±SD), n= 6 2.20 ± 0.09 2.19 ± 0.03 2.18 ± 0.06 2.20 ± 0.05 2.20 ± 0.08
Thickness (mm) (±SD), n= 6 2.06 ± 0.02 2.06 ± 0.02 2.06 ± 0.01 2.06 ± 0.01 2.06 ± 0.01
Friability (%) (±SD), n= 6 0.59 ± 0.06 0.43 ± 0.08 0.50 ± 0.05 0.54 ± 0.04 0.52 ± 0.07
% Drug content (±SD), n= 3 99.24 ± 0.10 98.79 ± 0.17 98.43 ± 0.15 99.13 ± 0.14 98.81 ± 0.20
Lag time in hours (i.e. time taken for
less than 10% of Naproxen release)
2.45 ± 0.97 2.40 ± 0.75 2.37 ± 0.98 2.44 ± 0.83 2.41 ± 0.67
Mean % cumulative drug release at
the end of 8 h
92.59 ± 0.47 92.37 ± 0.96 92.01 ± 0.65 92.16 ± 0.82 91.77 ± 0.70
Mean % cumulative drug release at
the end of 12 h
99.38 ± 0.69 98.97 ± 0.55 98.94 ± 0.87 99.24 ± 0.71 98.73 ± 0.91
72 M.A. Hadi et al.4. Conclusion
As the aim was to target Naproxen for the treatment of
rheumatoid arthritis according to chronotherapeutic pattern,
so a novel ileo-colonic targeted delivery system of Naproxen
was developed by ﬁlling ﬁfteen matrix-mini-tablets into an
empty HPMC capsule. By using microsomal enzyme
dependent and pH dependent polymers a total number of
twenty-four formulations were prepared and formulation
F18 was considered as the best formulation as it released
Naproxen after a lag time of 2.45 ± 0.97 h and
27.30 ± 0.86%, 92.59 ± 0.47%, 99.38 ± 0.69% at the end
of 5, 8, 12 h respectively. This formulation was also found to
be stable as per the ICH guidelines.
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